Vimarsana
Biggest News Aggregation in the World

Page 16 - Looking Statements News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Looking Statements. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Looking Statements Today - Breaking & Trending Today

Bullion Gold Starts Work on Bodo - Vimarsana News

Bullion Gold Starts Work on Bodo

Bullion Gold Resources Corp. will begin an initial exploration program starting June 2024 on its Bodo project which is located approximately 140 km north of the municipality of Chibougamau, in...

Bullion Gold Resources Corporation: Bullion Gold Starts Work on Bodo - Vimarsana News

Bullion Gold Resources Corporation: Bullion Gold Starts Work on Bodo

Montreal, Quebec--(Newsfile Corp. - May 21, 2024) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion Gold" or "The Company") will begin an initial exploration program starting June 2024 on its Bodo

EnerSys Publishes 2023 Sustainability Report Showcasing Notable Progress Towards Environmental, Social and Governance Goals - Vimarsana News

EnerSys Publishes 2023 Sustainability Report Showcasing Notable Progress Towards Environmental, Social and Governance Goals

EnerSys , a global leader in stored energy solutions for industrial applications, is proud to announce the publication of its 2023 Sustainability Report, showcasing notable progress in environmental,...

FDA Clears Cingulate to File for Marketing Approval of - Vimarsana News

FDA Clears Cingulate to File for Marketing Approval of

Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application Advancing Discussions with Commercialization Partners...

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD - Vimarsana News

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application        CTx-1301 Could Benefit >60% of ADHD Patients Currently ...